Lanthanide-based time-resolved luminescence immunoassays

A. K. Hagan · T. Zuchner

Received: 11 February 2011 / Revised: 12 April 2011 / Accepted: 19 April 2011 / Published online: 11 May 2011
© The Author(s) 2011. This article is published with open access at Springerlink.com

Abstract The sensitive and specific detection of analytes such as proteins in biological samples is critical for a variety of applications, for example disease diagnosis. In immunoassays a signal in response to the concentration of analyte present is generated by use of antibodies labeled with radioisotopes, luminophores, or enzymes. All immunoassays suffer to some extent from the problem of the background signal observed in the absence of analyte, which limits the sensitivity and dynamic range that can be achieved. This is especially the case for homogeneous immunoassays and surface measurements on tissue sections and membranes, which typically have a high background because of sample autofluorescence. One way of minimizing background in immunoassays involves the use of lanthanide chelate labels. Luminescent lanthanide complexes have exceedingly long-lived luminescence in comparison with conventional fluorophores, enabling the short-lived background interferences to be removed via time-gated acquisition and delivering greater assay sensitivity and a broader dynamic range. This review highlights the potential of using lanthanide luminescence to design sensitive and specific immunoassays. Techniques for labeling biomolecules with lanthanide chelate tags are discussed, with aspects of chelate design. Microtitre plate-based heterogeneous and homogeneous assays are reviewed and compared in terms of sensitivity, dynamic range, and convenience. The great potential of surface-based time-resolved imaging techniques for biomolecules on gels, membranes, and tissue sections using lanthanide tracers in proteomics applications is also emphasized.

Keywords Bioassays · Fluorescence/luminescence · Rare earth elements · Genomics/proteomics · Bioanalytical methods

Introduction

The detection of particular analytes is the cornerstone of analytical chemistry and is crucial for a plethora of different applications, ranging from protein detection to drug screening and mapping of biochemical pathways. Two vital features of the ideal assay are specificity and sensitivity—that is, the analyte of interest should be:

1. unambiguously detected even when potentially interfering substances are present in excess, and
2. detectable at the low concentrations typically required for most applications.

In protein detection, these problems are especially challenging to solve. First, biological samples are highly complex and contain a huge number of different proteins, making the detection of one specific protein a special challenge. Second, some proteins are expressed in extremely low copy numbers, especially in the early stages of disease. Third, biological samples containing proteins have high background fluorescence, making it difficult to obtain good sensitivity using simple fluorophores. Last, but not least, the difference between high-abundance and low-abundance proteins in one biological sample can span an estimated twelve orders of magnitude [1]. This requires detection methods with broad linear ranges. In general, time-resolved luminescence is an ideal tool to meet all of these challenges. As will be
discussed later, time-resolved luminescence not only provides excellent detection limits but also broadens the linear range of existing protein detection assays, because of the low background signals associated with this method.

In immunoassays the specificity is provided by antibodies raised against the analyte of interest, whereas sensitivity relies on some form of coupling of analyte–antibody binding with a detectable and quantifiable signal. In the simplest format this involves direct labeling of the antibody with a small molecule tag, for example a radioisotope or luminophore, which can then be detected using appropriate analytical devices. A variety of assay formats are also possible, including well plate-based assays in which the antigen of interest is either immobilized on the well plate surface or present in solution, membrane-based assays in which proteins are separated by gel electrophoresis and subsequently transferred to a membrane for detection, and direct staining of tissue sections for examination under a fluorescence microscope.

The objective of this critical review is to highlight the potential of lanthanide-based time-resolved luminescence for developing ultrasensitive immunoassays. The basic principles behind immunoassays (in the section “Immunoassays”) and time-resolved luminescence measurements (in the section “Lanthanide luminescence”) will be discussed, followed by a thorough overview of the main techniques for labeling biomolecules with lanthanides via various chelating groups (in the section “Chelator design and lanthanide labeling of biomolecules”). The remainder of the review will focus on reported immunoassays using lanthanide-based luminescence detection and will be divided into two main sections: the well-established field of microtitre plate-based assays, encompassing heterogeneous and homogeneous assays (the section “Microtitre plate-based assays”), and the nascent but promising field of imaging-based methods such as membrane imaging and time-resolved luminescence microscopy (in the section “Surface-based assays”).

**Immunoassays**

The term “immunoassay” refers to the use of antibodies raised against an analyte of interest (antigen) as a means of detecting the presence of that analyte. Because neither antibodies nor their binding to their antigens have high intrinsic detectability, the use of antibodies as detection reagents requires some form of labeling of the antibody with an easily detectable reporter molecule. The conceptually simplest reporters consist of antibodies directly labeled with either an enzyme or small molecule light absorbers, fluorophores, or radioisotopes, although indirect labeling via a species-specific secondary antibody or the biotin–streptavidin interaction results in greater versatility and some signal amplification.

The first immunoassays used antibodies labeled with radioisotopes that could subsequently be detected by use of scintillation counters. Although highly sensitive, the problems associated with radioisotopes (limited stability, safe disposal, etc.) have led to the development of alternative detection strategies, of which the most widespread is currently the use of antibody–enzyme conjugates, in which enzymatic turnover converts an uncolored substrate to a colored product which can be quantified colorimetrically. These assays have the advantage of amplification—that is, conversion of a single antibody–enzyme immunocomplex into multiple detectable molecules. However, the linear range of colorimetric detection is limited and the color-development process necessitates additional time, steps, and reagents. Antibody–fluorophore conjugates have the potential to eliminate some of these problems, because the fluorescence of the immunocomplex can be measured directly on the surface or in solution. However, they suffer from the disadvantage that no amplification occurs, requiring very bright luminescence output from each luminophore or high degrees of labeling. The latter can be difficult to achieve without compromising antibody activity or solubility. One way of achieving high sensitivity in luminescence-based assays entails the use of time-resolved luminescence measurements to minimize the sample background. The advantages of using time-resolved luminescence for immunodetection will be the focus of this review.

Four basic assay configurations are possible, depending on whether the immunoreaction occurs on a solid phase (heterogeneous) or in solution (homogeneous) and whether the antibody–analyte binding is monitored directly (non-competitive) or via displacement of a labeled antigen (competitive). Typical solid phases for a heterogeneous immunoassay include microtitre plates, membranes and tissue slices, to which the antigen is either bound directly or on which it is captured by use of an appropriate antibody (Fig. 1). The presence of this antigen can then be determined after binding an appropriately labeled antibody (or primary–secondary antibody combination) and measuring, e.g., the luminescence signal. A typical homogeneous non-competitive assay utilizes two differently labeled antibodies which interact with one another in some way (e.g. by luminescence resonance energy transfer, LRET) in the presence of the target antigen (Fig. 1), whereas a homogeneous competitive assay could involve a system whereby the target antigen displaces a labeled antigen analogue from a labeled antibody and thereby reduces the LRET intensity.

**Lanthanide luminescence**

Luminescence is the process in which a species absorbs light at one wavelength and subsequently emits it at a
second, generally higher, wavelength. The energy absorption excites the molecule from its ground state singlet electronic level (S₀) to a higher level (S₁, S₂, etc.) as shown in Fig. 2. Molecules excited to upper singlet energy levels (S₂ etc.) rapidly (~10⁻¹⁰ s) return to the lowest excited state S₁ without light emission, from which a number of radiative (fluorescence) and non-radiative transitions can occur to return the molecule to any of the rotational and/or vibrational levels of the ground electronic state S₀. The transition from S₁ to the triplet state T₁ is referred to as intersystem crossing and can be followed by relaxation to S₀ either radiatively (phosphorescence) or non-radiatively. In some circumstances T₁ can transfer the excitation energy to other species, for example chelated lanthanide ions (Eu³⁺, Tb³⁺, Dy³⁺, Sm³⁺), from which ion luminescence can occur [2]. This ligand–ion energy transfer is known as the antenna effect, and enables the observation of relatively intense luminescence signals from lanthanide ions, which absorb energy only poorly in the absence of ligand. Eu³⁺, the lanthanide ion that is most commonly used in bioanalytical applications, can accept energy from the ligand triplet state into any of several lower energy ⁵D₉ levels, with emission then occurring via transition from ⁵D₉ to any of the ground-state levels ⁷F₉ to give signals at several characteristic wavelengths (Fig. 2) [3]. The efficiency of this energy transfer and the intensity of the subsequent emission depend on both the ligand and the ion in question, and in particular on the energy gap between the ligand triplet level and the ion accepting level and the ability of the ligand to shield the ion from quenching inner sphere water molecules, as discussed later from the perspective of ligand design (in the section “Chelator design and lanthanide labeling of biomolecules”).

The key feature of lanthanide luminescence that renders it interesting bioanalytically is that lanthanide ions have exceedingly long-lived luminescence (μs to ms range), because the corresponding transitions are Laporte-forbidden. In comparison, luminescence from conventional fluorescent dyes and sample interferences occurs on a nanosecond scale. This unique feature means that lanthanide luminescence can be selectively measured even in the presence of other luminescent substances by time-gating the signal—that is, by only starting the acquisition cycle after the more rapid background fluorescence has decayed (Fig. 3). The benefit of this in terms of assay development is that the sensitivity of an assay depends strongly on the signal-to-background ratio that can be achieved. A high background signal for blank control samples containing no analyte worsens the limits of detection and quantification for real samples and limits the linear quantification range of an assay. Background in luminescence measurements arises from various sources, including the sample vessel or membrane, but the most important source in biological assays is generally the sample matrix. This is particularly the case for homogeneous assays in which interfering substances are not removed before measurement. A typical biological sample, for example serum or a tissue sample,
contains a multitude of luminescent substances, for example proteins and NAD+/H [4, 5], and the detection limits of various fluorophore–protein conjugates in serum have been reported to be 50 to 1000-fold higher than in buffer [6]. However, the vast majority of these interferences have standard short-lived fluorescence and can be filtered out by time-gated detection. This also has the consequence of broadening the linear range that can be achieved. Scattering of the excitation light by the instrument optics, sample vessel, and matrix is an additional problem with conventional fluorophores, because of their generally small Stokes shifts (<50 nm); this is circumvented by using lanthanide chelates (>150 nm). A final problem with conventional fluorophores is self-quenching because of substantial overlap between their excitation and emission spectra, meaning that multiply-labeled biomolecules fluoresce much less than might be expected from the degree of labeling. With their large Stokes shifts, narrow emission bands, and no overlap between excitation and emission spectra, lanthanide chelates are not susceptible to this problem and so are ideal candidates for highly sensitive protein-detection assays.

In the field of lanthanide-based time-resolved luminescence (TRL) immunoassays, the most common solid phases are microtitre plates. This has the practical advantage in terms of instrumentation that TRL capability can be incorporated into luminescence plate readers that are also capable of measuring other luminescence phenomena, for example fluorescence polarization or chemiluminescence. This provides a convenient and cost-effective measurement solution for the end user. A number of different plate readers with TRL measurement modes exist today. They vary in respect of the type of excitation sources, filters and/or monochromators, time-gating, and focus setups used. Excitation sources can be either flash lamps, lasers or UV-LEDs, although combinations of excitation sources (flash lamp plus UV-LED) do exist in some instruments in order to combine sensitivity with high flexibility (e.g. SpectraMax Paradigm, Molecular Devices). In particular, the strong 337 nm emission of a nitrogen laser is suitable for most europium chelates. Depending on the excitation source, instruments are either filter-based or monochromator-based. Whereas filter-based devices are generally regarded as more sensitive, they are not as flexible as monochromator-based devices (e.g. the Infinite m1000 system from Tecan). The time-delayed detection of the fluorescence signal is normally achieved by oscillator-controlled electronic devices. The strategy here is to ignore photon counts which arrive at the detector before a specific timepoint. A general challenge in TRL readers is the need for photomultiplier tubes with exceptionally low dark count rates. This is because the photon output of lanthanide-based TRL dyes is generally low compared with that of conventional fluorophores. With the recent development of various lanthanide based immunoassays as described below, more and more TRL-capable plate readers are becoming commercially available and more users are equipped to perform the assays described below.

Chelator design and lanthanide labeling of biomolecules

Introduction

The use of lanthanide ions in immunoassays requires their incorporation into the immunocomplex. This is achieved via the use of chelating agents, either by direct labeling of antibodies or by indirect labeling of secondary detection reagents. One secondary detection reagent is streptavidin, which can then be used with readily available biotinylated antibodies. A lanthanide chelator for use in immunoassays therefore consists of at least two parts—a chelating group for binding the lanthanide ion and some functionality for attachment to biomolecules. When the lanthanide-labeled biomolecule must be intrinsically luminescent, an additional sensitizing antenna moiety is required (as described in the section “Lanthanide luminescence”). The need to integrate the optimum requirements of each of these three components into a single molecule—that is, to create a stable complex which combines efficient light absorption, energy transfer, and emission, and which can be conveniently attached to biomolecules without interfering with their activity—is a major challenge in this field of research and the key points will be introduced in the section “Ligand requirements”. Numerous examples of specific lanthanide chelates from several structural classes will then be introduced in the sections “Non-luminescent chelates”, “PAC-based luminescent chelates”, “β-Diketone-based luminescent chelates”, and “Other luminescent chelates”). The focus here will be
on chelating structures that have been applied or have the potential to be applied to immunoassays rather than those designed for, e.g., electroluminescent materials applications, which have been excellently reviewed elsewhere [7].

Ligand requirements

**Chelating groups**

To incorporate lanthanide ions into luminescent complexes, chelating groups are required. Trivalent lanthanide cations Ln³⁺ are hard Lewis acids with a coordination number of 8–9 [8], requiring hard donors, for example carboxylates, β-diketonates and phosphonates, which contain nitrogen and oxygen donor atoms. Although lanthanide ions can be complexed by monodentate or bidentate ligands (e.g. 2-thenoyltrifluoroacetone, salicylic acid) and such complexes find application in some assays (described in the section “Heterogeneous assays”), most practical systems rely on the ability to carry the lanthanide ion as a “tag” on the biomolecule through the various assay steps. This implies that the complex has sufficient stability under the various assay conditions, and generally necessitates the use of multidentate chelators.

One major class of such chelators are the polyaminocarboxylates (PACs), for example the linear ethylenediaminetetraacetic acid (EDTA) and diethylenetriaminepentaacetic acid (DTPA) and their cyclic counterparts 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and 1,4,8,11-tetraazacyclotetradecane-1,4,8-triacetic acid (DO3A) (Fig. 4). These are the archetypal metal-sequestering agents that are used in a range of industrial applications and are readily available, inexpensive, and form soluble and highly stable complexes with lanthanides under basic conditions. The high stability of the lanthanide–PAC complexes stems from the ability of the multiple amine and carboxylate coordinating centers to wrap around the metal ion, and increases in the order EDTA<DTPA<DOTA with the denticity and from La to Lu across the lanthanide series with the decreasing ionic radius, with typical log K values for the lanthanide complexes being 10¹⁵–10²⁰, 10¹⁹–10²⁴, and 10²³–10²⁶ for EDTA, DTPA, and DOTA complexes, respectively [9]. An additional advantage for the higher-denticity PACs is that saturation of the lanthanide coordination sphere by the ligand excludes water and thereby minimizes aqueous quenching. These ligands also contain several possible derivatization points for installation of antenna moieties and reactive groups (see below).

A second group of lanthanide chelators that have found application in immunoassays are β-diketonates derived from the corresponding β-diketones under basic conditions (Fig. 4). Simple β-diketonates have two oxygen atoms available for coordination and tend to form 3:1 complexes with lanthanides, with the remaining vacant sites in the lanthanide coordination sphere being occupied by water molecules. Many of these ligands include aromatic antenna groups (see below) and their lanthanide complexes are intrinsically luminescent. Although a large number of lanthanide β-
After incorporation of a suitable lanthanide ion into a chelating complex, antenna regions are required to efficiently transfer excitation energy to the lanthanide ion. Such antenna groups consist of an highly π-conjugated aromatic or heteroaromatic system which efficiently absorbs light and transfers it to the lanthanide ion, increasing the molar extinction coefficient from \(10^4\)–\(10^5\) mol\(^{-1}\) L cm\(^{-1}\) for the uncomplexed trivalent cation to ca \(10^4\)–\(10^5\) mol\(^{-1}\) L cm\(^{-1}\) for a typical lanthanide–antenna complex [18, 20]. Typical antenna ligands include naphthalene, 1,10-phenanthroline, and 2,2′-bipyridine (Fig. 4). A systematic study of the complexes of 41 ligands with Eu\(^{3+}\) and Tb\(^{3+}\) revealed that the energy of the ligand triplet excited state is crucial in determining the sensitization efficiency of an antenna and should be at least 1,850 cm\(^{-1}\) higher than the lowest excited state of the lanthanide ion [21]. A smaller energy gap leads to a reduced quantum yield because of back energy transfer and quenching of the antenna triplet level, whereas a higher energy gap is acceptable because the energy transferred from the antenna transitions through the non-radiative excited states until it reaches the emittive level [18]. This energy gap requirement means that the choice of antenna depends somewhat on the lanthanide ion being used, and the optimum antenna for one lanthanide ion is seldom the optimum choice for another. In addition it is highly desirable that the excitation maximum of the antenna is above ca 350 nm, which enables the use of less expensive glass rather than quartz optics and avoids the excitation of other chromophores (e.g. Trp, NADH) in biological media. This is still a challenge in the development of new lanthanide-based dyes.

**Antennas**

There are essentially only two generally applicable chemical strategies for selective and efficient covalent attachment of luminophores or other small molecules to proteins—via either Lys amino groups (using e.g. active esters, isothiocyanates) or Cys thiols (using e.g. maleimides, ioacacetamide) (Fig. 4). These activated derivatives are ideally relatively stable under anhydrous conditions and can be conveniently coupled to proteins at neutral to slightly basic pH. Unlike conventional fluorophores, lanthanide chelates are seldom susceptible to self-quenching, and so it is generally desirable to incorporate as many lanthanide labels as possible into the final immunocomplex as can be achieved without affecting the immunological binding or physical properties (e.g. solubility). The maximum labeling degree that can be achieved depends on the protein, chelate, and reaction conditions in question, but 4–15 labels for a 150 kDa antibody using a simple PAC derivative is typical [22].

**Reactive groups for coupling to biomolecules**

There are essentially only two generally applicable chemical strategies for selective and efficient covalent attachment of luminophores or other small molecules to proteins—via either Lys amino groups (using e.g. active esters, isothiocyanates) or Cys thiols (using e.g. maleimides, ioacacetamide) (Fig. 4). These activated derivatives are ideally relatively stable under anhydrous conditions and can be conveniently coupled to proteins at neutral to slightly basic pH. Unlike conventional fluorophores, lanthanide chelates are seldom susceptible to self-quenching, and so it is generally desirable to incorporate as many lanthanide labels as possible into the final immunocomplex as can be achieved without affecting the immunological binding or physical properties (e.g. solubility). The maximum labeling degree that can be achieved depends on the protein, chelate, and reaction conditions in question, but 4–15 labels for a 150 kDa antibody using a simple PAC derivative is typical [22].
An alternative strategy to maximize the number of labels per antibody involves the use of labeled streptavidin as a universal detection system, because its binding affinity for biotin seems to tolerate higher labeling degrees, in addition to enabling a multivalency effect via multiply biotinylated antibodies [12, 23–26]. In a particularly extreme case, a macromolecular conjugate consisting of streptavidin, three units of thyroglobulin, and 480 lanthanide chelates has been reported [27, 28].

A novel recent alternative to labeling biomolecules with luminescent chelates that has recently emerged is the surface coating of a submicrometer luminescent bead with the biomolecule. Polystyrene beads (107 nm) containing >30,000 europium(III)−2-thenoyltrifluoroacetone complexes per particle are commercially available and have a carboxylic acid surface which can be used for covalent attachment of streptavidin or antibodies [29, 30]. The hydrophobic interior of such beads minimizes aqueous quenching and high luminescence intensities are obtained.

Although some of the labeling strategies lead to higher numbers of lanthanide dyes per protein than others, it is clear that coupling of lanthanide dyes to proteins is now a very well established technique and not a major challenge in terms of lanthanide dye compatibility in the field of immunoassays.

Non-luminescent chelates

The concept of using lanthanide chelates as labels in immunoassays was suggested thirty years ago by Wieder [31] and then by Soini and Hemmilä [6], and finally realized in 1983 with the advent of the DELFIA system [32]. This relies on a non-luminescent lanthanide tag which is liberated before measurement by addition of an enhancement solution. As such, simple reactive EDTA or DTPA-derived chelators which lack an antenna function can be utilized, for example cyclic DTPA anhydride (c-DTPAA), p-SCN-Bn-DTTA, and p-SCN-Bn-DTPA (Fig. 5). A compromise is required here between the need for chelate stability during storage and washing steps and rapid release of the lanthanide before measurement; one study revealed p-SCN-Bn-DTFA to be the optimum choice of those tested [33]. In this case, labeling degrees of 15–25 Eu³⁺ chelates per IgG were achieved and dissolution was achieved within 1 min of addition of the enhancement solution. Although c-DTPAA is a readily available and inexpensive alternative, it is poorly soluble and the reaction is difficult to control and may result in crosslinking of the biomolecule. A method for utilizing DOTA derivatives in the DELFIA system has also recently been reported; this uses a treatment step with 2.0 mol L⁻¹ HCl to release lanthanides from these more stable chelates before measurement [34]. A major advantage of the DELFIA system is the relative ease with which multiplexing can be achieved, because the same simple chelates can be used with any of the luminescent lanthanide ions, assuming enhancement solutions are available for all lanthanides present (typically Eu³⁺, Tb³⁺, Dy³⁺, Sm³⁺).

PAC-based luminescent chelates

A convenient means of preparing luminescent lanthanide chelates is to attach an antenna moiety to one of the carboxylates of DTPA, because the resulting product still has sufficiently high denticity to form stable chelates. Reaction of c-DTPAA (Fig. 5) with the commercially-available sensitizer carbostyril 124 (ε=12,000 mol⁻¹ L cm⁻¹(327 nm)) afforded DTPA-cs124 (Fig. 6), which forms luminescent complexes with both Eu³⁺ and Tb³⁺ [35]. The remaining anhydride of c-DTPAA can also be reacted with diamines and further converted to an isothiocyanate or maleimide derivative to enable facile coupling to proteins or DNA [36, 37]. Likewise, the recent synthesis of the ligand [EuL]H (Fig. 6) relied on attachment of a 1,10-phenanthroline-based sensitizers to c-DTPAA and subsequent reaction of an additional carboxylate with a maleimide derivative [17]. Coupling of the maleimide to proteins and incubation with Eu³⁺ enabled the detection of 100 amol lysozyme on PVDF membranes and 1.5 fmol BSA in SDS-PAGE gels, and a linear range spanning five orders of magnitude was

Fig. 5 Non-luminescent lanthanide chelators for use in DELFIA assays
demonstrated. The [EuL]H excitation spectrum covers an unusually wide range, making it compatible with a wide range of excitation sources from 310–365 nm.

β-Diketone-based luminescent chelates

Although simple β-diketones do not form sufficiently stable complexes to be used as labeling reagents, incorporation of two β-diketones into one molecule gives a tetradentate ligand which can be successfully used in immunoassays. The β-diketone units are held in place by a rigid or flexible spacer and also contain an aromatic or heteroaromatic antenna function; several such ligands have been developed (Fig. 7). The first example was BCDOT, which contains two biphenyl antennas for efficient light absorption ($\varepsilon=36,500$ mol$^{-1}$ L cm$^{-1}$ (330 nm)) and two sulfonyl chloride moieties for coupling to proteins [38]. For the BSA–BCDOT$_{47}$–Eu complex the detection limit was 83 fmol L$^{-1}$ in TOPO–SDS–NaHCO$_3$ solution and the method was shown to be linear over at least four orders of magnitude. The same authors subsequently developed the ligand BCOT, which was found to have similar properties for the free complex (ε=32,000 mol$^{-1}$ L cm$^{-1}$ (330 nm)) and the BSA–BCOT$_{40}$–Eu conjugate (detection limit 95 fmol L$^{-1}$) [39]. In both cases the luminescence intensity was enhanced by the synergistic TOPO ligand, partially quenched by phosphate, and resistant to dissolved oxygen. The thiophene-containing BCTOT has been used similarly [40]. All three ligands suffer from the disadvantage that the two sulfonyl chloride groups can potentially cause cross-linking of the proteins being labeled, although this can be avoided by prior blocking of one group by use of simple amines [38].

A second series of ligands containing more rigid terphenyl structures between the two β-diketones has also been developed (Fig. 7). A detection limit of 6.5 fmol L$^{-1}$ was reported for BSA–BHHCT$_{35}$–Eu [41]. Subsequent work revealed that the luminescence intensity could be increased eightfold by exchanging the C$_3$F$_7$ groups in BHHCT for CF$_3$ groups in BTBCT [42]. Potential drawbacks of these ligands include their poor aqueous solubility and the high reactivity of the sulfonyl chloride group, which may lead to poor reagent stability during storage or result in excessive labeling degrees and loss of bioactivity of the labeled molecules. In an attempt to develop a more mild reagent, the NHS ester derivative BHHST has also been prepared and found to have improved solubility and
reagent and immunoconjugate stability compared with BHHCT [43]. Some of these β-diketone ligands have also been successfully used to generate sensitive immunoassays, which will be the focus of the section “Surface measurement of directly luminescent chelates”.

Other luminescent chelates

BCPDA is a sulfonyl chloride-activated bathophenanthroline derivative (Fig. 8) and has been commercialized as part of the CyberFluor FiaGen product line [15]. The BCPDA–Eu complex has a moderate extinction coefficient at 325 nm ($\varepsilon \approx 15,200$ mol$^{-1}$ L cm$^{-1}$) and a long lifetime (0.44–0.76 ms) depending on conditions, with a luminescence that is again quenched by phosphate ions but insensitive to dissolved oxygen. A BSA–BCPDA$_{39}$–Eu conjugate has been prepared, and crosslinking between the twin sulfonyl chlorides was not observed. The detection limit for free BCPDA–Eu is approximately 10 pmol L$^{-1}$ [15] but, because most assays have relied on multiply-labeled streptavidin conjugates as a universal detection system, the actual detection limit is somewhat lower [12, 23–26]. A streptavidin–thyroglobulin$_3$–BCPDA$_{480}$ conjugate has also been reported [27, 28]. Although such heavily labeled conjugates provide access to lower detection limits, nonspecific binding of these large macromolecules to solid supports can present problems [44]. Measurements in these assays are typically performed in a dry well-plate using an excess of added Eu$^{3+}$, meaning that contamination by exogenous Eu$^{3+}$ is not an issue, which can be an advantage compared with the DELFIA system.

The Cis-Bio cryptate (Fig. 8) is a macropolycyclic ligand containing three bipyridine ligands with a dual chelator–antenna function, forming a cavity which is able to encapsulate Eu$^{3+}$ and Tb$^{3+}$ ions to form luminescent complexes [14]. Although this cavity results in tight metal chelation, the limitations of this system include the fact that addition of relatively large amounts of fluoride ions is necessary to exclude water molecules, and the excitation wavelength (307 nm) is somewhat shorter than desired. Nevertheless, europium complexes have found application as donors in homogeneous assays, for example the time-resolved amplification of cryptate emission (TRACE) and homogeneous time-resolved fluorescence (HTRF) assays from CisBio (described in the section “Homogeneous assays”) [45–47].

Chelate design: overview

A wide variety of different chelator, antenna, and protein-reactive structures are available for construction of lanthanide chelates for sensitive time-resolved luminescence assays, with the optimum system depending on the precise assay requirements. For DELFIA systems any of several non-luminescent PACs provide sufficient stability to carry the lanthanide tag through all requisite washing steps before luminescence development. Simple DTPA derivatives are generally preferred here, although luminescence development methods have also been established that enable the exploitation of the more stable DOTA derivatives. For assays requiring intrinsically luminescent chelates, this can be achieved either by simply grafting an appropriate antenna on to a PAC skeleton in the pendant chromophore strategy, or by using β-diketonate or heteroaromatic-containing antennas in the chromophoric chelate strategy. All of these routes have been shown to be capable of leading to lanthanide chelates that have sufficient stability, luminescence, and protein reactivity for the construction of sensitive immunoassays. It is worth noting here that the brightness (i.e. the product of quantum yield and extinction coefficient) of lanthanide-based luminophores is generally low compared with those of conventional fluorophores such as fluorescein. However, this potential limitation is overcome by the effective suppression of background signals provided by the time-gated detection, giving a net effect of increased dynamic range and more sensitive assays, as will be the focus of the next section.

Microtitre plate-based assays

Heterogeneous assays

Luminescence enhancement-based assays

The most commercially successful lanthanide-based immunoassay developed to date is the dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) from Wallac Oy, which can be used in heterogeneous competitive or non-competitive formats. In this system a non-fluorescent chelator,
for example DTPA (discussed in the section “Non-luminescent chelates”), is used to quantitatively carry the lanthanide tag through the immunoassay and luminescence is only developed before measurement upon addition of an enhancement solution. This consists of an antenna-containing β-diketone ligand (e.g. β-naphthoyltrifluoroacetone, NTA), a synergistic agent to exclude water from the lanthanide coordination sphere (e.g. triocetylphosphine oxide, TOPO), and a non-ionic detergent (e.g. Triton X-100) in an acidic phthalate buffer [48], which causes rapid dissociation of the lanthanide from the immunocomplex and forms a strongly luminescent micellar solution complex. All four of the luminescent lanthanides (Dy, Eu, Sm, Tb) can be utilized in the DELFIA assay, but differences in the emissive levels of the different ions necessitates use of different ligands and means that a single enhancement solution is not optimum for all ions. The detection limit for the micellar Eu$^{3+}$–NTA complex (ex. 340 nm, em. 613 nm, δΦ=0.7) is of the order of 50 fmol L$^{-1}$ [48], and Eu$^{3+}$ is the lanthanide of choice for single analyte assays. This leads to protein detection limits in the low ng L$^{-1}$ range (Table 1). Sm$^{3+}$ also forms luminescent complexes with NTA, albeit with 70-fold lower sensitivity (LOD 3.5 pmol L$^{-1}$), and is the preferred second lanthanide for dual analyte assays [49]. For detection of three or four analytes, Eu$^{3+}$ and Sm$^{3+}$ luminescence can be measured in an initial step via their NTA complexes, followed by measurement of Tb$^{3+}$ and Dy$^{3+}$ after addition of the dipicolinic acid ligand (4-(2',4',6'-trimethoxyphenyl)pyridine-2,6-diyldicarboxylic acid [50]. Four analyte assays can also be constructed using cofluorescence enhancement-based systems, in which inter-chelate energy transfer occurs from nearby non-luminescent lanthanide chelates, for example Gd$^{3+}$ or Y$^{3+}$ [49]. Both the two-step and one-step methods deliver detection limits in the 20 fmol L$^{-1}$–20 pmol L$^{-1}$ range for the four lanthanides. Three of the four luminescent lanthanides can also be efficiently sensitized by pivaloyltrifluoroacetone (LOD 0.4–20 pmol L$^{-1}$) but this is an inefficient ligand for Dy$^{3+}$ (LOD 1 nmol L$^{-1}$).

Besides its sensitivity and capacity for multiplexing, the DELFIA system has several additional advantages, including the commercial availability of all necessary protein labeling reagents and streptavidin–lanthanide conjugates, microtitre plates, assay buffers, and enhancement solutions. The solution-based measurement also minimizes any potential discrepancies arising from surface heterogeneity. One major limitation of the DELFIA system is the loss of spatial localization that results from the dissociation step, meaning that it cannot be applied to surface-based measurements (discussed in the section “Surface-based assays”). Contamination by exogenous lanthanide is also a problem and can affect assay reproducibility [51], although the relatively high ca 1 nmol L$^{-1}$ Eu$^{3+}$ concentration in human serum [52] should, in principle, be washed away during heterogeneous assays and not affect reproducibility. A minor practical disadvantage of the DELFIA system is the somewhat extensive washing required compared with conventional immunoassays. A typical lanthanide labeling degree is 15–25 chelates per IgG [33], and there does not seem to be any attempt in the literature to use, e.g., streptavidin–carrier protein conjugates to increase the number of lanthanide ions per immunocomplex. The same effect might also be achievable using macromolecular dendritic or polymeric chelators that could be bound to a detection antibody using the biotin–streptavidin interaction. Such a strategy could potentially dramatically increase the sensitivity of DELFIA assays by maximizing the signal intensity.

**Surface measurement of directly luminescent chelates**

The use of intrinsically luminescent lanthanide-containing detection reagents has several advantages compared with dissociation-enhanced solution measurements, including a reduction in the number of assay steps and washing cycles. The first such system developed was the CyberFluor FIAgen assay, which uses BCPDA-labeled (discussed in the section “Other luminescent chelates”) tracers, for example, streptavidin or streptavidin–thyroglobulin conjugates as widely applicable generic detection reagents [23, 24]. Luminescence is measured on the solid phase after drying in an excess of Eu$^{3+}$, which is necessary because of the limited chelate stability. An advantage of this is that the measurement is insensitive to exogenous Eu$^{3+}$ contamination. Furthermore, because of the large Stokes shift and corresponding insensitivity to self-quenching, these tracers can be synthesized with surprisingly high BCPDA loadings (15 BCPDA per streptavidin or 160 BCPDA per streptavidin–thyroglobulin conjugate) resulting in improved detection limits. In fact, the luminescence emitted per luminophore seems to increase upon increased loading, such that the TG–BCPDA$^{160}$ emits luminescence equivalent to 900 free BCPDA molecules [53]. In a non-competitive heterogeneous α-fetoprotein assay, the detection limits were improved fivefold compared with directly-labeled IgG by using streptavidin-BCPDA$^{15}$, and fivefold again by using the streptavidin–TG–BCPDA$^{150}$ conjugate (Table 1). A macromolecular streptavidin–TG$^{3.3}$–BCPDA$^{480}$ aggregate has also been prepared and shown to afford 8–26-fold reduced detection limits for seven different analytes [27]. A more recent development has been the use of streptavidin–polyvinylamine conjugates bearing 50–100 BCPDA moieties, resulting in detection limits of 1 ng L$^{-1}$ for PSA and a linear range spanning four orders of magnitude [54, 55]. This tracer seems to be optimum at present, although detection limits in the low ng L$^{-1}$ range have been reported for several proteins using the other macromolecular conjugates, and dynamic ranges for
Table 1 Detection limits and working ranges for selected heterogeneous immunoassays utilizing lanthanide-based time-resolved luminescence

| Analyte                          | Reporter                                      | Detection limit | Working range | Ref. |
|----------------------------------|-----------------------------------------------|-----------------|---------------|------|
| DELFIA                           |                                               |                 |               |      |
| Rabbit IgG                       | IgG–diazophenyl–EDTA–Eu                      | 25 ng L<sup>-1</sup> | –             | [48] |
|                                  | IgG–SCN–Bn–EDTA–Eu                           |                 |               |      |
| Hepatitis B surface antigen      | IgG–diazophenyl–EDTA–Eu                      | 500 ng L<sup>-1</sup> | >2            | [32] |
| Staphylococcal Enterotoxin B     | Unspecified IgG–Eu<sub>4,4</sub> conjugate   | 39 ng L<sup>-1</sup> | >2            | [51] |
| Yersinia pestis-specific F1 antigen | Unspecified IgG–Eu<sub>4,8</sub> conjugate | 24 ng L<sup>-1</sup> | >3            | [51] |
| Venezuelan equine encephalitis virus | IgG–(DTPA)<sub>21</sub>–Eu                  | 3.13 x 10<sup>9</sup> PFU L<sup>-1</sup> | >1            | [51] |
| Lipoprotein(a)                   | IgG–(DTPA)<sub>21</sub>–Tb                  | 2500000 ng L<sup>-1</sup> | >2            | [88] |
| PSA                              | IgG–DOTA–Eu                                  | 3.0 ng L<sup>-1</sup> | >3            | [57] |
| Clenbuterol                      | IgG–DOTA–Tb                                  | 10000 ng L<sup>-1</sup> | >2            | [89] |
| Hydrocortisone                   | IgG–DOTA–Tb                                  | 40000 ng L<sup>-1</sup> | >1            |      |
| Atrazine (comp.)                 | IgG–W8044–Eu                                 | 100 ng L<sup>-1</sup> | –             | [90] |
| FIAgen                           |                                               |                 |               |      |
| Rubella IgG                      | SA–BCPDA<sub>14</sub>–Eu                    | 10000 IU L<sup>-1</sup> | –             | [28] |
| Thyroxine-binding globulin       | SA–BCPDA–Eu                                  | 400 μg L<sup>-1</sup> | >2            | [26] |
| α-fetoprotein                    | IgG–BCPDA–Eu                                 | 5000 ng L<sup>-1</sup> | –             | [53] |
| α-fetoprotein                    | SA–BCPDA<sub>14</sub>–Eu                    | 1000 ng L<sup>-1</sup> | –             | [53] |
| α-fetoprotein                    | SA–TG–BCPDA<sub>160</sub>–Eu                | 200 ng L<sup>-1</sup> | –             | [53] |
| Choriogonadotrophin             | SA–BCPDA–Eu                                  | 1 IU L<sup>-1</sup> | >2            | [24] |
| Human pancreatic isomylase       | SA–TG–BCPDA–Eu                               | 1100 ng L<sup>-1</sup> | >2            | [91] |
| Growth hormone                   | SA–TG<sub>2.3</sub>–BCPDA<sub>480</sub>–Eu | 3 ng L<sup>-1</sup> | –             | [27] |
| Carcinobranchyonic antigen       | SA–TG<sub>2.3</sub>–BCPDA<sub>480</sub>–Eu | 11 ng L<sup>-1</sup> | –             | [27] |
| PSA                              | SA–B–PVA–BCPDA                               | 1 ng L<sup>-1</sup> | 4             | [54, 55] |
| Cortisol (comp.)                 | SA–BCPDA<sub>15</sub>–Eu                    | 10000 ng L<sup>-1</sup> | >1            | [25] |
| Digoxin (comp.)                  | SA–TG–BCPDA<sub>150</sub>–Eu                | 250 ng L<sup>-1</sup> | >1            | [92] |
| β-diketones                      |                                               |                 |               |      |
| α-fetoprotein                    | SA–BHHCT<sub>21</sub>–Eu                    | 4.1 pg L<sup>-1</sup> | –             | [41] |
| Thyroid-stimulating hormone      | SA–BSA<sub>18</sub>–BTBCT<sub>27</sub>–Eu   | 0.1 mIU L<sup>-1</sup> | >3            | [42] |
| T4 (comp.)                       | T4–BSA–BTBCT<sub>23</sub>–Eu                | 5.8 nmol L<sup>-1</sup> | –             | [42] |
| T4 (comp.)                       | T4–BSA–B, SA–BCTOT–Eu                       | 6.7 nmol L<sup>-1</sup> | –             | [40] |
| Nanoparticle-based               |                                               |                 |               |      |
| PSA                              | SA-coated Eu(β-NTA)<sub>3</sub>-doped polystyrene NPs | 1.6 ng L<sup>-1</sup> | 4             | [56] |
| PSA                              | IgG-coated Eu(β-NTA)<sub>3</sub>-doped polystyrene NPs | 0.21 ng L<sup>-1</sup> | 4             | [57] |
| Adenovirus                       | IgG-coated Eu(β-NTA)<sub>3</sub>-doped polystyrene NPs | 5650000 virus particles L<sup>-1</sup> | 4             | [58] |
| Hepatitis B surface antigen (HBsAg) | IgG-coated Eu(β-NTA)<sub>3</sub>-doped polystyrene NPs | 28 ng L<sup>-1</sup> | 4             | [59] |
| Listeria spp.                    | IgG-coated Eu(β-NTA)<sub>3</sub>-doped polystyrene NPs | 20000 CFU L<sup>-1</sup> | 4             | [60] |
| Anthrax PA                       | SA-coated polystyrene NPs, biotinylated anti-SA, SA–Eu | 10 ng L<sup>-1</sup> | 4             | [61] |
| Hepatitis B surface antigen (HBsAg) | F(ab')<sub>2</sub>-coated Eu(β-NTA)<sub>3</sub>-doped polystyrene NPs | 0.013 ng L<sup>-1</sup> | 4             | [62] |
| Anti-HIV-1 IgG                   | Pyridine-based Tb chelate-labeled HIV-1 antigen | n.d.            | –             |      |
| Enzyme-amplified lanthanide luminescence |                                             |                 |               |      |
| α-fetoprotein                    | IgG–ALP                                      | 1.4 ng L<sup>-1</sup> | >2            | [67] |
|                                  | Salicylic acid/salicylic acid/Tb–EDTA        |                 |               |      |
| α-fetoprotein                    | Bt-pAb SA–ALP                                | 0.15 ng L<sup>-1</sup> | >2            | [68] |
|                                  | 5-fluorosalicylic acid/Tb–EDTA               |                 |               |      |
| α-fetoprotein                    | IgG–ALP                                      | 3 ng L<sup>-1</sup> | >2            | [66] |
|                                  | Diflunisal phosphate/diflunisal/Tb–EDTA     |                 |               |      |
| Interleukin 6                    | SA–ALP                                       | 0.5 ng L<sup>-1</sup> (serum) | –             | [69] |
|                                  | Diflunisal phosphate/diflunisal/Tb–EDTA     |                 |               |      |
| PSA                              | SA–ALP                                       | 2 ng L<sup>-1</sup> | 10 ng L<sup>-1</sup> (serum) | [70] |

comp. = competitive
BCPDA-based assays are generally in the range of 2–3 orders of magnitude (Table 1).

Several of the β-diketone ligands (discussed in the section “β-Diketone-based luminescent chelates”) have also been used in immunoassays. Streptavidin-BHHCT23 has been developed as a generic detection reagent for luminescence measurement on either the solid phase or in solution after dissolution of the immunocomplex from the well plate [41]. For α-fetoprotein solid and solution phase detection limits of 46 pg L\(^{-1}\) and 4.1 pg L\(^{-1}\), respectively, were obtained (Table 1), which are at least four orders of magnitude lower than the aforementioned BCPDA-based assay and also superior to previous α-fetoprotein assays. A streptavidin-BSA\(_{1.8}\)-BTBCT\(_{77}\) conjugate has also been prepared and used for zeptomole detection of hTSH in a sandwich assay and found to give results comparable with those from a DELFIA-based system [42]. Two competitive assays for serum T4 have also been developed using T4–BSA–BTBCT\(_{23}\) or T4–BSA–biotin/streptavidin–BCTOT as competing analytes to give low nmol L\(^{-1}\) detection limits, which is sufficient for clinical diagnosis [40, 42].

Intrinsically luminescent lanthanide chelate-labeled detection reagents therefore provide an effective means of increasing sensitivity and linear range in immunoassays for a variety of different analytes. Performing luminescence measurements on a well plate surface necessitates a sufficient amount of tracer being present in the immunocomplex, and a greater number of lanthanide tags can typically be installed in biomolecules than conventional fluorophores, because of the lack of self-quenching. The number of lanthanide ions per immunocomplex can be increased even further by using extensively labeled proteins or other carrier macromolecules, although this has yet to be exploited for other dyes besides BCPDA and may be an attractive means of increasing sensitivity in other assays.

**Nanoparticle-based assays**

An interesting alternative to labeling an antibody or generic detection reagent with small-molecule lanthanide chelates is, instead, to incorporate the luminescent chelates inside a nanoparticle and coat the surface with the biomolecule. This method has resulted in broad linear ranges over, generally, four orders of magnitude and demonstrates the usefulness of time-resolved luminescence measurement especially in the field of protein detection. For example, with a typical 107-nm polystyrene bead containing 30,000 Eu(III)–2-thenoyltrifluoroacetone complexes, a much higher lanthanide-to-biomolecule ratio can be achieved than by conventional methods. The potential of streptavidin-coated luminescent nanoparticles was demonstrated in a PSA assay, giving zeptomole (10\(^{-21}\) mol) sensitivity and a linear range spanning four orders of magnitude (Table 1), a 100-fold increase over conventional methods using Eu-labeled streptavidin [56]. A modest increase in sensitivity was observed by using PSA-specific IgG-coated NPs (Table 1) [57]. IgG-coated nanoparticles have also been used for detection of an adenovirus, hepatitis B virus (HBsAg) and even bacteria (Table 1) [58–60]. An interesting signal amplification method has also been reported in a sandwich assay for anthrax toxin, in which a biotinylated secondary antibody is first bound to a streptavidin-coated luminescent nanoparticle before forming a macromolecular complex using biotinylated anti-streptavidin and streptavidin-Eu chelates [61].

Although these studies demonstrate the potential of lanthanide-doped nanoparticles, an interesting future development that has not been fully exploited is that of multicolor assays utilizing several different lanthanides. A dual analyte assay for hepatitis B surface antigen (HBsAg) and human immunodeficiency virus 1 (HIV-1) antibodies has been developed using F(ab)\(_{2}\)-coated Eu nanoparticles and a small molecule pyridine-based Tb chelate-labeled antigen [62]. In a move toward an entirely nanoparticle-based multiplexing assay, the synthesis of 45-nm poly(styrene–acrylic acid) nanoparticles containing each of the four luminescent lanthanides with appropriate sensitizers (>1,000 chelates per nanoparticle) has been reported and applied to an immunoassay to give detection limits for PSA of 1.6, 2.4, 10.1, and 114.2 ng L\(^{-1}\) for the Eu\(^{3+}\), Tb\(^{3+}\), Sm\(^{3+}\) and Dy\(^{3+}\)-doped nanoparticles, respectively [63]. One reason for the limited application of polystyrene nanoparticles may be the less-than optimum physical properties of the polymer itself, which include larger particle size, swelling, and leakage of the encapsulated molecules through surface defects [64]. A dual-lanthanide immunoassay for human and mouse IgG using 40 nm Eu-doped and Sm-doped silica nanoparticles has recently appeared but these multiplexing techniques have yet to be fully exploited [65]. These silica nanoparticles have several advantages over latex-based ones, including improved aqueous solubility and coupling chemistry, because of the silanol surface [64].

**Enzyme-amplified lanthanide luminescence (EALL)**

EALL assays utilize an enzyme as label, which converts a substrate into a product which is sufficiently different in terms of its chelating or spectroscopic properties to enable distinction between the two. The key advantage of this technique compared with the hitherto discussed assay formats is the enzymatic amplification step, although substrate conversion itself necessitates an additional assay step. Still, the potential for highly sensitive assays based on EALL is certainly one of the most promising in the field.

---

2 Springer
Most such assays use alkaline phosphatase (ALP) conjugates to convert salicylic acid phosphates into the corresponding salicylic acid derivative, the latter of which forms a luminescent complex with Tb$^{3+}$ and EDTA. The choice of substrate (Fig. 9, X substituent) depends on the assay requirements, with more soluble substrates being preferred for microtitre plate assays and more hydrophobic substrates being preferred for surface-based assays where signal localization is desired (discussed in the section “Surface-based assays”). The X substituent also affects the final luminescence properties of the chelate, and a comparison of 14 different ligands revealed that diflunisal (X=5-(2',4'-difluorophenyl)) gave amongst the most intense signals [66]. The limit of detection for ALP has been reported as 0.2 amol [44], and the use of diflunisal and related fluorinated substrates has led to detection limits in the low ng L$^{-1}$ range for analytes such as α-fetoprotein, interleukin 6, and PSA, even in serum (Table 1) [66–70]. These detection limits are at least equal to those using the luminophore-labeled tracers discussed earlier and confirm the value of EALL systems, especially when using widely available antibody–ALP conjugates.

Besides the ALP-based assays, xanthine oxidase–salicylaldehyde and β-galactosidase–salicyl-β-D-galactoside systems can also be used to generate salicylic acid–Tb(III)–EDTA complexes in solution [44]. These systems have seldom been used, however, perhaps because of their reduced sensitivity and the widespread availability of antibody–ALP conjugates. Hemin-mediated dimerization of p-hydroxybenzoic acid in the presence of H$_2$O$_2$ also generates a species capable of sensitizing Tb(III)–EDTA, although this has not yet been applied to an immunoassay format [71]. EALL systems have yet to be extensively developed for lanthanides other than Tb$^{3+}$, although glucose oxidase-mediated hydrolysis of 1,10-phenanthroline-2,9-dicarboxylic acid dihydrazide to the corresponding diacid has been shown to sensitize Eu$^{3+}$ [44]. One future objective in this area is the continued development of EALL systems which operate at neutral pH rather than the strongly alkaline systems above which require addition of EDTA to avoid precipitation of the lanthanide hydroxide, because the EDTA itself sensitizes lanthanides to a small extent and contributes to the background signal.

Homogeneous assays

Homogeneous immunoassays are potentially the most convenient assay format, in principle requiring only addition of the sample to the premixed reagents. Time-resolved luminescence can be extremely beneficial for such assays, because the inherently high background signals can be minimized. However, sensitive assays are much more difficult to achieve than with heterogeneous systems. Homogeneous assays are generally based on some form of LRET system, in which the presence of antigen either displaces a donor or acceptor-labeled antigen analogue...
from an acceptor or donor-labeled antibody (causing LRET to decrease in response to antigen concentration), or bridges two labeled antibodies (causing LRET to occur in response to antigen concentration; Fig. 1).

The most common system is the time-resolved amplification by cryptate emission (TRACE; also known as homogeneous time-resolved fluorescence, HTRF) system developed by Cisbio International, which relies on a europium cryptate label (Fig. 8) as donor and a crosslinked allophycocyanin (XL665) as acceptor [45]. One surprising benefit of this system is that the efficient LRET between these two species actually results in a signal increase compared with radiative deactivation of the isolated Eu cryptate [46]. This system was first developed for an assay for prolactin in which two IgGs were separately labeled with the cryptate and XL665 [45]. In the presence of analyte, 337 nm excitation of the cryptate is followed by energy transfer to the XL665 which ultimately emits at 665 nm with a lifetime of 0.25 ms and can be measured and compared with the reference 620 nm cryptate emission for unbound IgG, resulting in a detection limit of 0.3 μg L⁻¹ prolactin (Table 2). A detection limit of <600 ng L⁻¹ for interleukin-13 has also been obtained [47].

Small-molecule acceptors can also be used in LRET-based systems. In a competitive assay for urinary albumin, albumin-Cy5 was used as a tracer to accept energy from the pyridine-based luminescent donor ITC–TEKES–Eu, giving a rather high detection limit in the mg L⁻¹ range [72]. The working range of this assay was nonetheless sufficient for diagnosis of microalbuminuria.

Antibody Fab fragment-coated Eu³⁺ chelate-doped 92 nm nanoparticles have been used in conjunction with an estradiol–AlexaFluor 680 acceptor to detect pmol L⁻¹ levels of estradiol in a competitive assay [73]. Sensitivity in this assay was increased 20-fold compared with assays using soluble chelates [74]. Nanoparticle-based donors and acceptors have also been combined in a PSA assay in which anti-PSA antibodies on the two surfaces bring together the donor and acceptor nanoparticles and lead to a detection limit of 0.1 μg L⁻¹ [75].

The key benefit of using lanthanide complexes in homogeneous assays arises from the fact that such assays are ideally performed by direct addition of the biological sample to the premixed assay reagents. In comparison with heterogeneous assays in which background interferences can be removed by multiple washing steps, these species are still present during measurement in a homogeneous assay, and the use of lanthanide chelates and time-gated acquisition enables the background signal to be efficiently removed.

### Surface-based assays

Despite the proven benefits of using lanthanide chelates in microtitre plate-based assays, the extension of time-resolved luminescence techniques to surface-based assays has been less widespread. The ability to use lanthanide chelates on surfaces used in key proteomics techniques, for example membranes, gels, and tissue slices, would be a major breakthrough, because these materials typically have high autofluorescence backgrounds which could be removed by using time-resolved techniques. However, a lack of suitable instrumentation has hindered the development of these techniques. This is especially true for the time-resolved luminescence measurement of polyacrylamide gels, nitrocellulose, or PVDF membranes to enable application of gel-based protein analysis systems, for example immunoblot and SDS-PAGE. To the best of our knowledge, only one instrument for time-resolved fluorescence measurement of gels and membranes is currently commercially available (SpectraMax Paradigm, Molecular Devices). This prototype shows the high potential of TRL measurements in gel-based analysis systems [17]. Interestingly, a linear range of five orders of magnitude was reported for this instrument, demonstrating the high potential of time-resolved luminescence for immunoblot applications.

The advantages of time-resolved luminescence detection for microscopy studies, especially for highly autofluorescent tissue materials, are obvious. Surface-based assays require intrinsically luminescent lanthanide chelates, because spatial resolution would be lost in a dissociation-enhanced format. Although several europium-based stains for visualization of tissue slices and membranes have been

### Table 2 Detection limits and working ranges for selected homogeneous immunoassays utilizing lanthanide-based time-resolved luminescence

| Analyte          | Reporters                                      | Detection limit | Working range | Ref. |
|------------------|------------------------------------------------|-----------------|---------------|------|
| Prolactin        | Donor: IgG–TBP–Eu                              | 300 ng L⁻¹      | –             | [45] |
| Interleukin-13   | Donor: IgG–Eu cryptate                        | <600 ng L⁻¹     | –             | [47] |
| Interleukin-13   | Acceptor: IgG–APC                             |                 |               |      |
|                  | Donor: IgG–Eu cryptate                        |                 |               |      |
|                  | Acceptor: IgG–APC                             |                 |               |      |
| Albumin (comp.)  | Donor: IgG–TEKES–ITC₂₇–Eu                      | 5.5 mg L⁻¹      | >1            | [72] |
|                  | Acceptor: albumin–Cy₅₁₆                        |                 |               |      |
| Estradiol (comp.)| Donor: Fab-coated–Eu–chelate NP               | 70 pmol L⁻¹     | –             | [73] |
|                  | Acceptor: estradiol–Alexa 680                 |                 |               |      |

[72] A.K. Hagan, T. Zuchner
developed since the 1960s [76, 77], the first lanthanide-labeled immunoreagents for dedicated specific surface-based detection did not appear until 1988 [5]. In this case, anti-rabbit IgG was labeled with a europium–W1014 chelate (structure unspecified) and used for immunohistochemical staining using a conventional fluorescence microscope. The use of dehydrated histological sections was necessary because of aqueous quenching, and both intensity and stability under steady-state excitation were inferior to those of fluorescent-labeled IgG.

Full exploitation of the potential of lanthanide-labeled biomolecules required the development of a luminescence microscope capable of time-gated detection; this was first applied to lanthanide-labeled biomolecules in 1990 [78]. These early experiments demonstrated that 100–300 nm milled Eu$^{3+}$-doped yttrium oxy sulfide polycarboxylic acid-stabilized nanoparticle phosphors coated with IgG or avidin could successfully bind corresponding targets on latex beads and cell surfaces. A similar prototype instrument was developed and used for immunohistochemical analysis of various specimens after staining with antisera and streptavidin coupled to a pyridine-based europium chelate, enabling efficient removal of background luminescence and equal sensitivity to fluorescent-labeled and enzyme-labeled antibodies [79]. Labeling of antibodies with the stable Eu–W8044 chelate (structure unspecified) has also been found to reduce the autofluorescence of glutaraldehyde-fixed colon cancer cells and enable signal-to-background ratios of 2400:1 to be obtained [80]. Likewise, Eu–terpyridine-labeled antibodies have been shown to improve signal-to-background ratios in islet cells by a factor of 12 compared with conventional fluorescein-labeled antibodies [81]. Similarly, a Eu–terpyridine chelate has been attached to anti-PSA antibodies and bound to prostate cells [82]. Several β-diketone dyes have also been used for microscopy studies. Antibodies labeled with BPPCT (Fig. 7) have been used for detection of cysts of the water-borne pathogen Giardia lamblia on filter membranes, resulting in a 30-fold increase in contrast relative to conventional immunoreagents [83]. Giardia and Cryptosporidium have also been detected by use of BHHST-labeled antibodies, which resulted in tenfold enhancement of signal-to-noise ratio [43, 84]. It has also been shown recently that the luminescence of surface-based BHHCT complexes is enhanced in the presence of silver nanostructures, leading to twofold increased brightness during detection of G. lamblia cells [85]. These techniques enable sensitive detection of pathogens in environmental water samples containing multiple autofluorescent species, for example algae, mineral particles, and organic debris.

For generic detection reagents, streptavidin–thryoglobulin–BCPDA (discussed in the section “Surface measurement of directly luminescent chelates”) has been used for analysis of tissue-bound biotinylated anti-myosin antibodies, and its photostability has been reported to be superior to that of previous chelates [86]. Streptavidin–Eu chelate nanoprobes have also been used, enabling detection of single nanoparticles using a TRL microscope [82]. In model studies using biotinylated PSA, a linear range of two orders of magnitude was reported, although the authors note that biological variation is expected to constitute the major source of error when attempting to quantify antigens in tissue sections. An unspecified streptavidin–Eu chelate has also been used for detection of biotin-tyramide after enzymatic deposition by an antibody–peroxidase conjugate, enabling signal amplification [87].

Considering all results described for surface-based assays, it is clear that this area is an ideal field of application for time resolved luminescence. However, few instruments are currently able to fully exploit this possibility.

**Conclusions**

The objective of this review has been to explain the benefits of lanthanide-based time-resolved luminescence measurements in immunoassays. Using time-gated acquisition the background signal can be efficiently suppressed, enabling more sensitive detection of proteins using lanthanide chelate tags than is possible with chromophore-based or conventional fluorophore-based labels. This ultimately leads to lower detection limits and wider linear ranges for the analyte in question. This is especially valuable for protein detection where these criteria are of particular importance and where high autofluorescence is normally observed when time-gated detection is not used.

Although it is difficult to reliably compare sensitivities reported for different lanthanide chelates obtained for different analytes and assay configurations in different laboratories, the heterogeneous DELFIA, FIAgen, nanoparticle, and EALL-based assays are all capable of delivering sensitivity in the lower ng L$^{-1}$ range. For the DELFIA system this is derived from an intensely luminescent solution complex, whereas the other assays rely either on the extensive incorporation of lanthanides into a multi-protein complex or nanoparticle, or on enzymatic amplification to increase the number of detectable labels per immunocomplex. It would be interesting, therefore, to investigate whether the sensitivity of the DELFIA system could be increased even further by use of macromolecular chelates that incorporate hundreds of lanthanide ions rather than the 15–25 ions used with single antibodies. The sensitivity of the EALL assays could also, perhaps, be improved via more extensive testing of enzyme–substrate pairs than the predominantly ALP–salicylic acid-based systems that have been used to date. For the homogeneous
assays that have been developed the sensitivity is typically in the high ng L$^{-1}$ range, so these are more suitable for applications where speed is more important than sensitivity.

A key advantage of lanthanide time-resolved luminescence-based assays is the increased linear range because of suppression of the background signal, and many of the heterogeneous assays discussed above are able, in principle, to provide linear ranges spanning five orders of magnitude. However, for the actual assays discussed here, linear ranges of 2–3 orders of magnitude are typical for the DELFIA, FIAgen, β-diketonate, and EALL-based assays, with nanoparticle-based assays consistently delivering linear ranges spanning at least four orders of magnitude. With the difference between high abundance and low abundance proteins spanning an estimated twelve orders of magnitude [1], it is clear that further improvements in instrumentation and assay development are desirable here. In conclusion, more emphasis should be given to the use of time-resolved luminescence as an ideal tool to meet the unique challenges of the field of protein detection, for example broad linear ranges, high sensitivity, and excellent signal-to-background ratios.

Acknowledgments The authors gratefully acknowledge the helpful comments on this manuscript of Professor Ralf Hoffmann. This work was supported by BMBF Innoprofile, project number 03IP604.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

1. Corthals G, Wasinger V, Hochstrasser D, Sanchez J-C (2000) The dynamic range of protein expression: a challenge for proteomic research. Electrophoresis 21:1104–1115
2. Weissman S (1942) Intramolecular energy transfer: the fluorescence of complexes of europium. J Chem Phys 10:214–217
3. Hemmilä I, Laitala V (2005) Progress in lanthanides as luminescent probes. J Fluoresc 15(4):529–542
4. Aubin J (1979) Autofluorescence of viable cultured mammalian cells. J Histochem Cytochem 27(1):36–43
5. Soini E, Pelliniemi L, Hemmilä I, Mukkala V-M, Kankare J, Fröjdman K (1988) Lanthanide chelates as new fluorochrome labels for cytochemistry. J Histochem Cytochem 36(11):1449–1451
6. Soini E, Hemmilä I (1979) Fluoroimmunoassay: present status and key problems. Clin Chem 25(3):353–361
7. Eliseeva S, Bünzli J-C (2010) Lanthanide luminescence for functional materials and bio-sciences. Chem Soc Rev 39(1):189–227
8. Karraker D (1970) Coordination of trivalent lanthanide ions. J Chem Educ 47(6):424–430
9. Cacheris W, Nickle S, Sherry A (1987) Thermodynamic study of lanthanide complexes of 1,4,7-Triazacyclononane-N, N′, N″-triacetic Acid and 1,4,7,10-Tetraazaacyclodecane-N, N′, N″, N‴-tetraacetic Acid. Inorg Chem 26:960–962
10. Binnemans K (2005) Rare-earth beta-diketonates. In: Gschneidner K Jr, Bünzli J-C, Pecharsky V (eds) Handbook on the physics and chemistry of rare earths, vol 35. Elsevier B. V., pp 107–272
11. Yamada S, Miyoshi F, Kano K, Ogawa T (1981) Highly sensitive laser fluorometry of europium(III) with 1,1,1-trifluoro-4-(2-thienyl)-2,4-butanediene. Anal Chim Acta 127:195–198
12. Diamandis E (1988) Immunoassays with time-resolved fluorescence spectroscopy: principles and applications. Clin Biochem 21:139–150
13. Moore E, Samuel A, Raymond K (2009) From antenna to assay: lessons learned in lanthanide luminescence. Acc Chem Res 42(4):542–552
14. Alpha B, Lehn J-M, Mathis G (1987) Energy transfer luminescence of europium(III) and Terbium(III) cryptates of macrocyclic poly(pyridine) ligands. Angew Chem Int Ed Engl 26(3):266–267
15. Evangelista R, Pollak A, Allore B, Templeton E, Morton R, Diamandis E (1988) A new europium chelate for protein labelling and time-resolved fluorometric applications. Clin Biochem 21:173–178
16. Selvin P, Rana T, Hearst J (1994) Luminescence resonance energy transfer. J Am Chem Soc 116(13):6029–6030
17. Zuchner T, Schumer F, Berger-Hoffmann R, Müller K, Lukas M, Zeckert K, Marx J, Hennig H, Hoffmann R (2009) Highly sensitive protein detection based on lanthanide chelates with antenna ligands providing a linear range of five orders of magnitude. Anal Chem 81(22):9449–9453
18. Armelao L, Quici S, Barigelletti F, Accorsi G, Bottaro G, Cavazzini M, Tondello E (2010) Design of luminescent lanthanide complexes: from molecules to highly efficient photo-emitting materials. Coord Chem Rev 254:487–505
19. Cross J, Dadabhoy A, Sammes P (2004) The sensitivity of the lehn cryptand-europium and terbium (III) complexes to anions compared to a coordinatively saturated systems. J Lumin 110(3):113–124
20. Sabbatini N, Guardigli M, Lehn J-M (1993) Lanthanide lanthanide complexes as photochemical supramolecular devices. Coord Chem Rev 123:201–228
21. Latva M, Takalo H, Mukkala V-M, Matachescu C, Rodríguez-Ubías J, Kankare J (1997) Correlation between the lowest triplet state energy level of the ligand and lanthanide(III) luminescence quantum yield. J Lumin 75:149–169
22. Perkin Elmer product manual for DELFIA(R) Eu-Labeling Reagent 1244–301 (2000) http://shop.perkinelmer.com/content/Manuals/man_1244-301.pdf. Accessed 5 May 2011
23. Chan M, Bellem A, Diamandis E (1987) Time-resolved immunofluorometric assay of alpha-fetoprotein in serum and amniotic fluid, with a novel detection system. Clin Chem 33(11):2000–2003
24. Khosravi M, Diamandis E (1987) Immunofluorometric of chorio-gonadotropin by time-resolved fluorescence spectroscopy, with a new europium chelate as label. Clin Chem 33(11):1994–1999
25. Diamandis E, Bhayana V, Conway K, Reichstein E, Papanastasiou-Diamandis A (1988) Time-resolved fluorimno-assay of cortisol in serum with a europium chelate as label. Clin Biochem 21:291–296
26. Tan Y, Khosravi M, Diamandis E (1989) Time-resolved immunofluorometric assay for thyroxine-binding globulin in serum. J Immunnoassay 10(4):413–428
27. Morton R, Diamandis E (1990) Streptavidin-based macromolecular complex labeled with a europium chelator suitable for time-resolved fluorescence immunoassay applications. Anal Chem 62(17):1841–1845
28. Shankaran P, Reichstein E, Khosravi M, Diamandis E (1990) Detection of immunoglobulins G and M to rubella virus by
time-resolved immunofluorometry. J Clin Microbiol 28(3):573–579
32. Siitari H, Hemmilä I, Soini E, Lövgren T, Koistinen V (1983) Detection of hepatitis B surface antigen using time-resolved fluorimunoassay. Nature 301:258–260
33. Mikkula V-M, Mikola H, Hemmilä I (1989) The synthesis and use of activated N-Benzyl derivatives of diethylene-triaminetetra-acetic acids: alternative reagents for labeling of antibodies with metal ions. Anal Biochem 176:319–325
34. De Silva C, Vagner J, Lynch R, Gillies R, Hruby V (2010) Optimization of time-resolved fluorescence assay for detection of europium-tetraazacyclododecyltetracetic acid–labeled ligand-receptor interactions. Anal Biochem 398:15–23
35. Li M, Selvin P (1995) Luminescent polyaminocarboxylate chelates of terbium and europium: the effect of chelate structure. J Am Chem Soc 117(31):8132–8138
36. Li M, Selvin P (1997) Amine-reactive forms of a luminescent diethylene-triaminepentaacetic acid chelate of terbium and europium: attachment to dna and energy transfer measurements. Bioconjug Chem 8(2):127–132
37. Chen J, Selvin P (1999) Thirol-reactive luminescent chelates of terbium and europium. Bioconjug Chem 10(2):311–315
38. Yuan J, Matsumoto K (1996) Synthesis of a new tetratandentate β-diketonate–europium chelate that can be covalently bound to proteins in time-resolved fluorescence. Anal Sci 12:695–699
39. Yuan J, Matsumoto K (1997) Synthesis of a new tetratandentate β-diketonate–europium chelate and its application for time-resolved fluorimetry of albumin. J Pharm Biomed Anal 15:1397–1403
40. Wu F-B, Han S-Q, Zhang C, He V-F (2002) Synthesis of a highly fluorescent β-diketone–europium chelate and its utility in time-resolved fluorimunoassay of serum total thyroxine. Anal Chem 74(22):5882–5889
41. Yuan J, Matsumoto K, Kimura H (1998) A new tetratandentate β-diketonate–europium chelate that can be covalently bound to proteins for time-resolved fluorimunoassay. Anal Chem 70(3):596–601
42. Wu F-B, Zhang C (2002) A new europium β-diketone chelate for ultrasensitive time-resolved fluorescence immunnoassays. Anal Biochem 311:57–67
43. Connally R, Veal D, Piper J (2004) Time-resolved fluorescence microscopy using an improved europium chelate BHHST for the in situ detection of Cryptosporidium and Giardia. Microsc Res Tech 64:312–322
44. Gudgin Dickson E, Pollak A, Diamandis E (1995) Time-resolved detection of lanthanide luminescence for ultrasensitive biochemical assays. J Photochem Photobiol B Biol 27:3–19
45. Mathis G (1993) Rare earth cryptates and homogeneous fluoroimunoassays with human sera. Clin Chem 39(9):1953–1959
46. Mathis G (1995) Probing molecular interactions with homogeneous techniques based on rare earth cryptates and fluorescence energy transfer. Clin Chem 41(9):1391–1397
47. Enomoto K, Araki A, Nakajima T, Ohta H, Dohi K, Préaudat M, Seguin P, Mathis G, Suzuki R, Kominami G, Takemoto H (2002) High-throughput miniaturized immunoassay for human interleukin-13 secreted from NK3.3 cells using homogenous time-resolved fluorescence. J Pharm Biomed Anal 28:73–79
48. Hemmilä I, Dakuib S, Mikkala V-M, Siitari H, Lövgren T (1984) Europium as a label in time-resolved immunofluorometric assays. Anal Biochem 127:335–343
49. Hemmilä I (1995) Luminescent lanthanide chelates – a way to more sensitive diagnostic methods. J Alloy Comp 225:480–485
50. Hemmilä I, Mikkala V-M, Latva M, Kiilholma P (1993) Di- and tetracarboxylate derivatives of pyridines, bipyridines and terpyridines as lumogenic reagents for time-resolved fluorometric determination of terbium and dysprosium. J Biochem Biophys Methods 26:283–290
51. Smith D, Rossi C, Kijek T, Henchal E, Ludwig G (2001) Comparison of dissociation-enhanced lanthanide fluorescent immunnoassays to enzyme-linked immunosorbent assays for detection of staphylococcal enterotoxin B, V. pestis-F1 antigen, and Venezuelan equine encephalitis virus. Clin Diag Lab Immunol 8(6):1070–1075
52. Accardo S, Cutoio M (1986) Concentrations of lanthanides in plasma and synovial fluid in rheumatoid arthritis. Clin Chem 32(8):1596
53. Diamandis E, Morton R, Reichstein E, Khosravi M (1989) Multiple fluorescence labeling with europium chelators. Application to time-resolved fluorimunoassays. Anal Chem 61(1):48–53
54. Scorilas A, Diamandis E (2000) Polyvinylamine–streptavidin complexes labeled with a europium chelator: a universal detection reagent for solid-phase time-resolved fluorometric applications. Clin Biochem 33(5):345–350
55. Scorilas A, Bjartell A, Lilja H, Moller C, Diamandis E (2000) Streptavidin–polyvinylamine conjugates labeled with a europium chelator: applications in immunoassay, immunohistochemistry, and microarrays. Clin Chem 46(9):1450–1455
56. Hämä H, Soukka T, Lönnberg S, Paukkunen J, Härmä H, Lönngren T, Lövgren T (2000) Zeptomole detection sensitivity of prostate-specific antigen in a rapid microtitre plate assay using time-resolved fluorescence. Luminescence 15:351–355
57. Soukka T, Antonen K, Hämä H, Pelkkikangas A-M, Huhtinen P, Lövgren T (2003) Highly sensitive immunoassay of free prostate-specific antigen in serum using europium(III) nanoparticle label technology, Clin Chim Acta 328:45–58
58. Valanne A, Huopalohit S, Soukka T, Vainionpää R, Lövgren T, Härma H (2005) A sensitive adenosine immunosassay as a model for using nanoparticle label technology in virus diagnostics. J Clin Virol 33:217–223
59. Valanne A, Huopalohit S, Vainionpää R, Lövgren T, Härma H (2005) Rapid and sensitive HBsAg immunoassay based on fluorescent nanoparticles labels and time-resolved detection. J Virol Methods 129:83–90
60. Jaakohuhta S, Hämä H, Tuomola M, Lövgren T (2007) Sensitive immunoassay for human interleukin-13 secreted from NK3.3 cells using homogenous time-resolved fluorescence. J Pharm Biomed Anal 28:73–79
application of Eu(III), Tb(III), Sm(III), and Dy(III) lanthanide chelate nanoparticle labels. Anal Chem 77:2643–2648
64. Wang F, Tan W, Zhang Y, Fan X, Wang M (2006) Luminescent nanomaterials for biological labelling. Nanotechnology 17:R1–R13
65. Murray K, Cao Y-C, Ali S, Hanley Q (2010) Lanthanide doped silica nanoparticles applied to multiplexed immunoassays. Analyst 135:2132–2138
66. Veiopoulou C, Lianidou E, Ioannou P, Efstatthiou C (1996) Comparative study of fluorescent ternary terbium complexes. Application in enzyme amplified fluorometric immunoassay for a-fetoprotein. Anal Chim Acta 335:177–184
67. Lianidou E, Ioannou P, Sacharidou E (1994) Second derivative synchronous scanning fluorescence spectrometry as a sensitive detection technique in immunoassays. Application to the determination of a-fetoprotein. Anal Chim Acta 290:159–165
68. Christopoulous T, Diamandis E (1992) Enzymatically amplified time-resolved fluorescence immunoassay with terbium chelates. Anal Chem 64(4):342–346
69. Barthellos L, Lianidou E, Ioannou P (1998) A highly sensitive enzyme-amplified lanthanide luminescence immunoassay for interleukin 6. Clin Chem 44(6):1351–1353
70. Yu H, Diamandis E (1993) Ultrasensitive time-resolved immuno-fluorometric assay of prostate-specific antigen in serum and preliminary clinical studies. Clin Chem 39(10):2108–2114
71. Zheng X-Y, Lu J-Z, Zhu Q-Z, Xu J-G, Li Q-G (1997) Study of a lanthanide fluorescence system with a coupled reaction based on hemin catalysis. Analyst 122:455–458
72. Qin Q-P, Peltola O, Pettersson K (2003) Time-resolved fluorescence resonance energy transfer assay for point-of-care testing of urinary albumin. Clin Chem 49(7):1105–1113
73. Kokko L, Sandberg K, Lövgren T, Soukka T (2004) Europium(III) chelate-dyed nanoparticles as donors in a homogeneous proximity-based immunoassay for estradiol. Anal Chim Acta 503:155–162
74. Kokko L, Kokko T, Lövgren T, Soukka T (2008) Particulate and soluble Eu(III)-chelates as donor labels in homogeneous fluorescence energy transfer based immunoassay. Anal Chim Acta 606:72–79
75. Valanne A, Lindroos H, Lövgren T, Soukka T (2005) A novel homogeneous assay format utilising proximity dependent fluorescence energy transfer between adjacent particulate labels. Anal Chim Acta 539:251–256
76. Saff W Jr, Dyer D, Mori K (1969) Fluorescent europium chelate stain. J Biocatal (9):224–248
77. Kemper C, Berggren K, Diwu Z, Patton W (2001) An improved, luminescent europium-based stain for detection of electroblotted proteins on nitrocellulose or polyvinylidene difluoride membranes. Electrophoresis 22:881–889
78. Beverloo H, van Schadewijk A, van Gelderenboele S, Tanke H (1990) Inorganic phosphors as new luminescent labels for immunocytochemistry and time-resolved microscopy. Cytometry 11:784–792
79. Seveus L, Väisälä M, Syrjänen S, Sandberg M, Kuusisto A, Harju R, Salo J, Hemmilä I, Kojola H, Soini E (1992) Time-resolved fluorescence imaging of europium chelate label in immunohistochemistry and in situ hybridization. Cytometry 13:329–338
80. Seveus L, Väisälä M, Hemmilä I, Kojola H, Roomans G, Soini E (1994) Use of fluorescent europium chelates as labels in microsor appears to allow the detection of proteins in permanent mounting and also to reduce autofluorescence and long-term stability. Microsc Res Tech 28:149–154
81. Rulli M, Kuusisto A, Salo J, Kojola H, Simell O (1997) Time-resolved fluorescence imaging in islet cell autoantibody quantitation. J Immunol Methods 208:169–179
82. Väisänen V, Härnä H, Lila H, Bjartell A (2000) Time-resolved fluorescence imaging for quantitative histochemistry using lanthanide chelates in nanoparticles and conjugated to monoclonal antibodies. Luminescence 15:389–397
83. Connolly R, Veal D, Piper J (2002) High resolution detection of fluorescently labeled microorganisms in environmental samples using time-resolved fluorescence microscopy. FEMS Microbiol Ecol 41:239–245
84. Connolly R, Jin D, Piper J (2006) High intensity solid-state uv source for time-gated luminescence microscopy. Cytometry 69A:1020–1027
85. Deng W, Jin D, Drozdowicz-Tomsia K, Yuan J, Goldys E (2010) Europium chelate (BHHCT–Eu3+) and its metal nanostructure enhanced luminescence applied to bioassays and time-gated bioimaging. Langmuir 26(12):10036–10043
86. Marriott G, Heidecker M, Diamandis E, Yan-Marriott Y (1994) Time-resolved delayed luminescence image microscopy using an europium ion chelate complex. Biophys J 67:957–965
87. de Haas R, Verwoerd N, van der Corput M, van Gijselwijk R, Siitari H, Tanke H (1996) The use of peroxidase-mediated deposition of biotin–tyramide in combination with time-resolved fluorescence imaging of europium chelate label in immunohistochemistry and in situ hybridization. J Histochem Cytochem 44 (10):1091–1099
88. Jürgens G, Hermann A, Aktuna D, Petek W (1992) Dissociation-enhanced lanthanide fluorescence immunoassay of lipoprotein(a) in serum. Clin Chem 38(6):853–859
89. Bacigalupo M, Meroni G, Secundo F, Scalera C, Quici S (2009) Antibodies conjugated with new highly luminescent Eu3+ and Tb3+ chelates as markers for time resolved immunoassays. Application to simultaneous determination of clenbetalen and free cortisol in horse urine. Talanta 80:954–958
90. Worborg M, Camann K (1993) Determination of triazine herbicides with time-resolved fluorimunoassay using europium(III)-chelates. Fresenius J Anal Chem 346:757–760
91. Diamandis E, Papanastasiou-Diamandi A, Lustig V, Khosravi M, Tan A (1989) Time-resolved immunofluorometric assay of human pancreatic isoamylase in serum, with use of two monoclonal Antibodies. Clin Chem 35(9):1915–1920
92. Papanastasiou-Diamandi A, Conway K, Diamandis E (1989) Digoxin immunoassay with monoclonal and polyclonal antibodies using time-resolved fluorometry. J Pharm Sci 78(8):617–621